Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Apr;144(8):1017-28.
doi: 10.1038/sj.bjp.0706153.

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

Shannon M Bates  1 , Jeffrey I Weitz
Affiliations
Review

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

Shannon M Bates et al. Br J Pharmacol. 2005 Apr.

Abstract

The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
New anticoagulants and their targets in the coagulation pathway.
See this image and copyright information in PMC

References

    1. ABRAHAM E., REINHART K., OPAL S., DEMEYER I., DOIG C., RODRIGUEZ A.L., BEALE R., SVOBODA P., LATERRE P.F., SIMON S., LIGHT B., SPAPEN H., STONE J., SEIBERT A., PECKELSEN C., DE DEYNE C., POSTIER R., PETTILA V., ARTIGAS A., PERCELL S.R., SHU V., ZWINGELSTEIN C., TOBIAS J., POOLE L., STOLZENBACH J.C., CREASEY A.A., OPTIMIST TRIAL STUDY GROUP Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–247. - PubMed
    1. ABRAHAM E., REINHART K., SVOBODA P., SEIBERT A., OLTHOFF D., DAL NOGARE A., POSTIER R., HEMPELMANN G., BUTLER T., MARTIN E., ZWINGELSTEIN C., PERCELL S., SHU V., LEIGHTON A., CREASEY A.A. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med. 2001;29:8081–8089. - PubMed
    1. AGNELLI G., BERGQVIST D., COHEN A., GALLUS A., GENT M.A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study J. Thromb. Haemost. 2003Suppl 1Abstr. #OC006
    1. ALBERS G.W., DALEN J., LAUPACIS A., MANNING W.J., PETERSEN P., SINGER D.E. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119:194S–206S. - PubMed
    1. ALEXANDER J.H., DYKE C.K., YANG H., BECKER R.C., HASSELBLAD V., ZILLMAN L.A., KLEIMAN N.S., HOCHMAN J.S., BERGER P.B., COHEN E.A., LINCOFF A.M., SAINT-JACQUES H., CHETCUTI S., BURTON J.R., BUERGLER J.M., SPENCE F.P., SHIMOTO Y., ROBERTSON T.L., KUNITADA S., BOVILL E.G., ARMSTRONG P.W., HARRINGTON R.A., The XaNADU-PCI PILOT Investigators Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PIC Pilot. J. Thromb. Haemost. 2004;2:234–241. - PubMed

Publication types

MeSH terms